Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Ultsch, BernhardKöster, Ingrid
Reinhold, Thomas
Siedler, Anette
Krause, Gerard

Icks, Andrea
Schubert, Ingrid
Wichmann, Ole
Issue Date
2013-12
Metadata
Show full item recordAbstract
After acquiring a varicella virus infection, the virus can reactivate and cause herpes zoster (HZ)--a painful skin rash. A complication of HZ is long-term persistence of pain after the rash has resolved (so-called postherpetic neuralgia, PHN). We aimed to describe the epidemiology of HZ/PHN and to estimate HZ/PHN-related costs in the German statutory health insurance (SHI) system (~85% of the total population). Treatment data of one large SHI was utilized, containing data on approximately 240,000 insured and their utilisation of services in 2004-2009. Identification of HZ- and PHN-cases was performed based on 'International Statistical Classification of Diseases' and specific medications using a control-group design. Incidences per 1,000 person-years (PY) and cost-of-illness for 1 year following HZ-onset considering the payer and societal perspective were calculated. All amounts were inflated to 2010 Euros. Population-figures were standardised and extrapolated to the total SHI-population in Germany in 2010. A mean annual incidence of 5.79 HZ-cases per 1,000 PY was observed, translating into an estimated 403,625 HZ-cases per year in the total SHI-population. Approximately 5% of HZ-cases developed PHN. One HZ-case caused on average euro 210 and euro 376 of costs from the payer and societal perspective, respectively. The development of PHN generated additional costs of euro 1,123 (euro 1,645 societal perspective). Total annual HZ/PHN-related costs were estimated at euro 182 million (euro 105 million) to society (payer). HZ and PHN place a considerable burden on the German SHI-system. Since HZ-vaccines will soon be available, a health-economic evaluation of these vaccines should be conducted.Citation
Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. 2013, 14 (6):1015-26 Eur J Health EconAffiliation
Epidemiology, Helmholtz Centre for infection research, Inhoffenstr. 7, 38124 Braunschweig, Germany.PubMed ID
23271349Type
ArticleLanguage
enISSN
1618-7601ae974a485f413a2113503eed53cd6c53
10.1007/s10198-012-0452-1
Scopus Count
The following license files are associated with this item:
Related articles
- Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
- Authors: Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O
- Issue date: 2013 Sep 26
- Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
- Authors: Préaud E, Uhart M, Böhm K, Aidelsburger P, Anger D, Bianic F, Largeron N
- Issue date: 2015
- Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
- Authors: Pellissier JM, Brisson M, Levin MJ
- Issue date: 2007 Nov 28
- Herpes zoster and postherpetic neuralgia in Catalonia (Spain).
- Authors: Salleras L, Salleras M, Salvador P, Soldevila N, Prat A, Garrido P, Domínguez A
- Issue date: 2015
- Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study.
- Authors: Schmidt-Ott R, Schutter U, Simon J, Nautrup BP, von Krempelhuber A, Gopala K, Anastassopoulou A, Guignard A, Curran D, Matthews S, Espié E
- Issue date: 2018 May